Emergent BioSolutions (EBS) SVP awarded 104,282 restricted stock units

Rhea-AI Filing Summary

Emergent BioSolutions Inc. reported that SVP and General Counsel Jessica Perl received a grant of 104,282 shares of common stock in the form of restricted stock units as compensation. The grant was approved by the board’s Compensation Committee on March 2, 2026 and became effective after stockholders approved an amended stock incentive plan on April 29, 2026.

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the approval date, contingent on continued service. Each restricted stock unit converts into one share of common stock, bringing Perl’s direct holdings to 165,286 shares following this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Perl Jessica

Role SVP, General Counsel, Corp Sec

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	104,282	$0.00	--

Holdings After Transaction: Common Stock — 165,286 shares (Direct, null)

Footnotes (1)

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Key Figures

RSU grant size: 104,282 shares Shares after transaction: 165,286 shares Grant price per share: $0.00 per share +3 more

6 metrics

RSU grant size 104,282 shares Restricted stock units granted on approval under Amended Stock Incentive Plan

Shares after transaction 165,286 shares Total common shares directly owned after grant

Grant price per share $0.00 per share Form 4 transaction price field for RSU grant

Plan approval date April 29, 2026 Stockholders approved Amended Stock Incentive Plan

Committee approval date March 2, 2026 Compensation Committee approved the RSU grant

Vesting schedule 3 annual installments RSUs vest annually beginning on anniversary of approval date

Key Terms

restricted stock units, Compensation Committee, Amended Stock Incentive Plan, continued service

4 terms

restricted stock units financial

"Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Compensation Committee financial

"The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Amended Stock Incentive Plan financial

"subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan")"

continued service financial

"These restricted stock units vest in three annual installments ... assuming continued service with the Company."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perl Jessica

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel, Corp Sec

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026	04/29/2026(1)	A		104,282(2)	A	$0	165,286	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

2. Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

Remarks:

	/s/ Richard S. Lindahl, Attorney-in-fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Emergent BioSolutions (EBS) report for Jessica Perl?

Emergent BioSolutions reported that SVP and General Counsel Jessica Perl received 104,282 restricted stock units of common stock. The award is a compensation grant approved by the Compensation Committee and tied to the company’s Amended Stock Incentive Plan.

How many Emergent BioSolutions (EBS) shares does Jessica Perl hold after this grant?

After the restricted stock unit grant, Jessica Perl beneficially owns 165,286 shares of Emergent BioSolutions common stock directly. This figure reflects her position immediately following the award reported in the Form 4 insider transaction filing.

What are the vesting terms of Jessica Perl’s restricted stock units at EBS?

The restricted stock units granted to Jessica Perl vest in three equal annual installments. Vesting begins on the anniversary of the approval date, and continued service with Emergent BioSolutions is required for each installment to vest into common shares.

Were shareholders involved in approving Jessica Perl’s stock award at Emergent BioSolutions?

Yes. The restricted stock unit grant was contingent on stockholder approval of an amendment to Emergent BioSolutions’ 2006 Stock Incentive Plan. Stockholders approved the Amended Stock Incentive Plan on April 29, 2026, allowing the award to proceed under that plan.

How does each restricted stock unit in Jessica Perl’s grant at EBS work?

Each restricted stock unit in the grant represents the right to receive one share of Emergent BioSolutions common stock. Delivery occurs upon vesting, subject to the terms and adjustment provisions of the Amended Stock Incentive Plan and the specific grant agreement.